Ganetespib, a heat shock protein 90 inhibitor, used in clinical trials for the treatment of non-small cell lung carcinoma with EGFR, KRAS, or ALK mutations, was effective in all cell lines with a stronger inhibition in CRMM2. Here, EGFR is linked to non-small cell lung carcinoma.